Literature DB >> 24300991

Gold nanorods-bombesin conjugate as a potential targeted imaging agent for detection of breast cancer.

Zahra Heidari1, Reyhaneh Sariri2, Mojtaba Salouti3.   

Abstract

Photoacoustic imaging (PAI) is a hybrid biomedical imaging modality that offers both strong optical absorption contrast and high ultrasonic resolution. PAI is capable of in vivo molecular imaging, thus facilitating further molecular and cellular characterization of cancer. In this study, Gold nanorods (GNRs) were synthesized and coated with polyethyleneglycol (PEG). Then, the PEG-GNRs were conjugated with bombesin (BBN), a cancer seeking peptide, for production of a potential photoacoustic targeting imaging agent for detection of breast cancer. The optical property, biocompatibility, stability and in vitro/in vivo binding affinities of GNR-PEG-BBN for breast cancer cells were investigated. UV-vis spectroscopy confirmed the conjugation of bombesin with PEG-coated GNRs. The stability assessment proved high optical stability of GNR-PEG-BBN in human blood serum up to 12h. Cytotoxicity study showed biocompatibility of GNR-PEG-BBN conjugate. Molecular targeting ability was approved in cells over expressing gastrin-releasing peptide (GRP) receptor (breast cancer cell line) in comparison with cells that do not express GRP receptor (skin fibroblast cell line). The selective accumulation of GNR-PEG-BBN was demonstrated in breast tumor in comparison with unconjugated gold nanorods, following the intravenous administration of GNR-PEG-BBN to breast tumor-bearing mice. This study demonstrated the potential of GNR-PEG-BBN as a photoacoustic imaging agent that can provide improved specificity and sensitivity for breast cancer detection.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bombesin; Breast cancer; GRP receptor; Photoacoustic imaging agent; Targeting

Mesh:

Substances:

Year:  2013        PMID: 24300991     DOI: 10.1016/j.jphotobiol.2013.10.019

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  7 in total

Review 1.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 2.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

3.  Water-Soluble Chitosan Conjugated DOTA-Bombesin Peptide Capped Gold Nanoparticles as a Targeted Therapeutic Agent for Prostate Cancer.

Authors:  Theeranan Tangthong; Thananchai Piroonpan; Velaphi C Thipe; Menka Khoobchandani; Kavita Katti; Kattesh V Katti; Wanvimol Pasanphan
Journal:  Nanotechnol Sci Appl       Date:  2021-03-18

4.  Application of Dual-Enhanced Surface-Enhanced Raman Scattering Probe Technology in the Diagnosis of Tumor Cells in Vitro.

Authors:  Yinping Zhao; Yawei Kong; Liwen Chen; Han Sheng; Yiyan Fei; Lan Mi; Bei Li; Jiong Ma
Journal:  Molecules       Date:  2022-06-02       Impact factor: 4.927

5.  BBN conjugated GNPs: a new targeting contrast agent for imaging of breast cancer in radiology.

Authors:  Mojtaba Salouti; Faranak Saghatchi
Journal:  IET Nanobiotechnol       Date:  2017-08       Impact factor: 1.847

6.  In vitro assessment of antibody-conjugated gold nanorods for systemic injections.

Authors:  Sonia Centi; Francesca Tatini; Fulvio Ratto; Alessio Gnerucci; Raffaella Mercatelli; Giovanni Romano; Ida Landini; Stefania Nobili; Andrea Ravalli; Giovanna Marrazza; Enrico Mini; Franco Fusi; Roberto Pini
Journal:  J Nanobiotechnology       Date:  2014-12-05       Impact factor: 10.435

7.  Histochemistry for nanomedicine: Novelty in tradition.

Authors:  Manuela Malatesta
Journal:  Eur J Histochem       Date:  2021-12-27       Impact factor: 3.188

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.